Linked e-resources
Details
Table of Contents
Intro
Foreword
Preface
Contents
1: Rationale, Definition, and History of Transarterial Chemoembolization
1.1 From 60 S to Late 70 S: From Diagnostic to Therapeutic Arteriography
1.2 From Late 70 S: The Conventional TACE
1.3 From the 80 S: Degradable Starch Microsphere TACE
1.4 The 90 S-2000: Evidences on TACE
1.5 From Early 2000: Drug-Eluting Beads TACE
1.6 From 2008 to Nowadays
References
2: Transarterial Chemoembolization (TACE): Indications
2.1 Introduction
2.2 TACE for Intermediate- Stage HCC
2.3 TACE for Non-intermediate-Stage HCC
2.4 TACE for Bridging and Downstaging HCC to LT
2.5 TACE for Liver-Dominant Primary Cholangiocellular and Metastatic Disease
References
3: Access and Material
3.1 Access
3.2 Materials and Technique
3.2.1 Novel Anti-Reflux Microcatheters. Pressure-Assisted Embolization
References
4: Preprocedure Workup
4.1 Preprocedure Workup
4.1.1 Outpatient Examination
4.1.1.1 ECOG Performance Status
4.1.1.2 Laboratory Test
4.1.1.3 Imaging
4.1.1.4 Echocardiogram
4.1.1.5 Scores for Initial TACE
4.2 Periprocedure Workup
4.2.1 Medications
4.2.2 Patient Management and Monitoring
4.2.3 Expert Nurse Team
References
5: CBCT and Software
5.1 CBCT
5.1.1 Introduction
5.1.2 Technique Principles
5.1.3 Patient Preparation
5.1.4 Radiation Dose Principle and Concern
5.1.5 Application in Transarterial Chemoembolization
5.1.5.1 CBCT during Hepatic Artery Injection
5.1.5.2 Dual-Phase CBCT
5.1.5.3 CBCT without Contrast Media
5.1.5.4 CBCT during Portography
5.1.5.5 CBCT Perfusion
5.1.5.6 Potential Clinical Implication of CBCT
5.2 Software Guidance
5.2.1 Introduction
5.2.2 Applications
5.2.2.1 Conclusion
References
6: Conventional TACE (cTACE)
6.1 HCC
6.1.1 Conventional TACE in HCC: Technique and Standardised Protocol
6.1.1.1 Haemodynamics in the Liver and HCC
6.1.1.2 Conventional TACE (cTACE) Protocol
6.1.1.3 Chemotherapeutic Agents
6.1.1.4 Embolic Agents
6.2 Conventional TACE (cTACE) Technique: Superselective TACE
6.2.1 Limitation of TACE and Necessity for Curative TACE
6.3 Conventional TACE in Intrahepatic Cholangiocarcinoma (ICC)
6.3.1 Background
6.3.2 Clinical Evidence and Tumour Response
6.3.3 Conventional TACE in Liver Metastases
6.3.3.1 From Colorectal Tumours (CRLM)
6.3.3.2 From Neuroendocrine Tumours (NETs)
6.3.3.3 From Other Types of Tumours
References
7: Drug-Eluting Embolic TACE (DEB-TACE)
7.1 TACE with Drug-Eluting Microspheres (DEM-TACE)
7.1.1 DEM-TACE in Hepatocellular Carcinoma
7.1.1.1 Drugs
7.1.1.2 Bead Size
7.1.1.3 Procedural Specifications
7.1.1.4 Results
7.1.1.5 Bland Embolization Versus TACE and Treatment Endpoint
7.1.2 DEM-TACE in Other Tumors
7.1.2.1 DEM-TACE for Intrahepatic Cholangiocarcinoma
Foreword
Preface
Contents
1: Rationale, Definition, and History of Transarterial Chemoembolization
1.1 From 60 S to Late 70 S: From Diagnostic to Therapeutic Arteriography
1.2 From Late 70 S: The Conventional TACE
1.3 From the 80 S: Degradable Starch Microsphere TACE
1.4 The 90 S-2000: Evidences on TACE
1.5 From Early 2000: Drug-Eluting Beads TACE
1.6 From 2008 to Nowadays
References
2: Transarterial Chemoembolization (TACE): Indications
2.1 Introduction
2.2 TACE for Intermediate- Stage HCC
2.3 TACE for Non-intermediate-Stage HCC
2.4 TACE for Bridging and Downstaging HCC to LT
2.5 TACE for Liver-Dominant Primary Cholangiocellular and Metastatic Disease
References
3: Access and Material
3.1 Access
3.2 Materials and Technique
3.2.1 Novel Anti-Reflux Microcatheters. Pressure-Assisted Embolization
References
4: Preprocedure Workup
4.1 Preprocedure Workup
4.1.1 Outpatient Examination
4.1.1.1 ECOG Performance Status
4.1.1.2 Laboratory Test
4.1.1.3 Imaging
4.1.1.4 Echocardiogram
4.1.1.5 Scores for Initial TACE
4.2 Periprocedure Workup
4.2.1 Medications
4.2.2 Patient Management and Monitoring
4.2.3 Expert Nurse Team
References
5: CBCT and Software
5.1 CBCT
5.1.1 Introduction
5.1.2 Technique Principles
5.1.3 Patient Preparation
5.1.4 Radiation Dose Principle and Concern
5.1.5 Application in Transarterial Chemoembolization
5.1.5.1 CBCT during Hepatic Artery Injection
5.1.5.2 Dual-Phase CBCT
5.1.5.3 CBCT without Contrast Media
5.1.5.4 CBCT during Portography
5.1.5.5 CBCT Perfusion
5.1.5.6 Potential Clinical Implication of CBCT
5.2 Software Guidance
5.2.1 Introduction
5.2.2 Applications
5.2.2.1 Conclusion
References
6: Conventional TACE (cTACE)
6.1 HCC
6.1.1 Conventional TACE in HCC: Technique and Standardised Protocol
6.1.1.1 Haemodynamics in the Liver and HCC
6.1.1.2 Conventional TACE (cTACE) Protocol
6.1.1.3 Chemotherapeutic Agents
6.1.1.4 Embolic Agents
6.2 Conventional TACE (cTACE) Technique: Superselective TACE
6.2.1 Limitation of TACE and Necessity for Curative TACE
6.3 Conventional TACE in Intrahepatic Cholangiocarcinoma (ICC)
6.3.1 Background
6.3.2 Clinical Evidence and Tumour Response
6.3.3 Conventional TACE in Liver Metastases
6.3.3.1 From Colorectal Tumours (CRLM)
6.3.3.2 From Neuroendocrine Tumours (NETs)
6.3.3.3 From Other Types of Tumours
References
7: Drug-Eluting Embolic TACE (DEB-TACE)
7.1 TACE with Drug-Eluting Microspheres (DEM-TACE)
7.1.1 DEM-TACE in Hepatocellular Carcinoma
7.1.1.1 Drugs
7.1.1.2 Bead Size
7.1.1.3 Procedural Specifications
7.1.1.4 Results
7.1.1.5 Bland Embolization Versus TACE and Treatment Endpoint
7.1.2 DEM-TACE in Other Tumors
7.1.2.1 DEM-TACE for Intrahepatic Cholangiocarcinoma